OpenEvidence Stock Price, Valuation & IPO
Private company — OpenEvidence is privately held. Its shares are not listed on any public exchange and can only be accessed through private secondary transactions.
Status source: AXEVIL investment team
$613.00 per share (AXEVIL consensus estimate)
Source: AXEVIL consensus of recent secondary transactions · as of 4 March 2026
Last round valuation: $15B
Source: D-3, September 2026, post-money
Total raised: $735M+
Data last updated: 15 October 2026
About OpenEvidence
ChatGPT for doctors — the #1 AI clinical-decision-support platform in the US. 740K physicians (45% of all US doctors), 10,000+ clinics, and 100M+ patients reached. Monetized through targeted pharma advertising (CPM $70–150+).
OpenEvidence is the fastest-growing AI clinical-decision-support service in the US and the most-used medical search engine among physicians: 740,000 doctors (45% of all US physicians) across 10,000+ clinics. ARR grew from $7M to $150M over 2025. It monetizes through targeted pharma advertising with $1B+ in inventory. Founder Daniel Nadler previously built Kensho (sold to S&P Global for $550M).
- Sector: AI Healthcare
- Headquarters: Miami, FL, USA
- Founded: 2022
Key highlights
- A physician shortage and burnout crisis. The US is projected to face a shortage of up to 100,000 doctors by 2030. Meanwhile, 63% of physicians report burnout symptoms and 25% plan to leave the profession within 2 years. AI is the only way to scale medical expertise and ease cognitive load without proportionally growing headcount.
- 45% of US doctors are already on the platform. That critical mass creates a powerful network effect — every new clinic makes the platform more valuable for everyone on it. More than 50K new doctors join every month, and at this pace OpenEvidence could reach 70%+ of the US market by the end of 2026.
- Explosive monetization growth — with huge upside still untapped. Ad-based monetization only began in December 2024, yet ARR grew from $7M to $150M (+2,000%) over 2025. And that's just the start: current ad inventory exceeds $1B a year, of which only a small fraction is monetized so far.
- EHR integration is the next growth lever. A pilot with Sutter Health and Epic embeds the AI directly into electronic health records, opening a path from an ad model to a subscription model with 5-10x higher ARPU. The revenue potential from EHR integrations is $2B+.
- Global expansion. There are 15 million doctors and 30 million nurses worldwide, and less than 5% are covered today. English-speaking markets (UK, Canada, Australia) are the priority for the next 2-3 years, followed by the EU and Latin America — a global TAM 10x the size of the US market.
Funding rounds
| Date | Round | Price / share | Post-money valuation |
|---|---|---|---|
| 24 September 2026 | D-3 | $595.40 | $15B |
| 14 April 2026 | D-2 | $487.38 | $12B |
| 21 January 2026 | D | $487.38 | $12B |
| 20 October 2025 | C2 | $252.32 | $6B |
| 15 July 2025 | B1 | $150.87 | $3.5B |
| 19 February 2025 | A | $43.04 | $1B |
| 7 June 2024 | Seed4 | $28.92 | $618M |
| 31 July 2023 | Seed2 | $28.92 | $560M |
Latest news
Frequently asked questions
How can I buy OpenEvidence stock before the IPO?
Not on a public exchange — OpenEvidence is privately held. Shares change hands only in private secondary transactions. AXEVIL structures those as dedicated US special purpose vehicles for accredited investors, subject to availability and to the rules of your jurisdiction.
What is the OpenEvidence stock price?
A private company has no single official share price. AXEVIL's consensus estimate is $613.00 per share as of 4 March 2026. Its most recent round implied a post-money valuation of $15B (September 2026).
What is OpenEvidence's valuation (net worth)?
OpenEvidence's most recent funding round valued the company at $15B post-money (September 2026) — the latest primary-market measure of what the company is worth. Secondary trades can price its shares above or below that round.
When will OpenEvidence IPO?
No listing has been announced. AXEVIL does not forecast IPO dates — this page states what has actually been filed or reported, with the date it was last checked.
Is OpenEvidence publicly traded?
No. OpenEvidence is a private company and its shares are not listed on any public exchange.
Does OpenEvidence have a stock symbol?
No. OpenEvidence has no ticker symbol because its shares are not listed on any exchange; a symbol is assigned only at an IPO or direct listing.
Similar companies
- Skild AI — Robotics
- Discord — Consumer & Retail
- Lovable — Artificial Intelligence
- ClickHouse — Data / Analytics
- Base Power — Energy
- Applied Intuition — Transportation
Risk disclosure
Nothing on this page is an offer to sell or a solicitation to buy any security, and it is not investment advice. Valuations and share prices shown here are AXEVIL estimates built from primary sources — filings, announced rounds and completed secondary transactions — not quoted market prices, and they can be revised. Private-company shares are illiquid, may be impossible to sell, and the entire amount invested can be lost. Availability depends on your jurisdiction and on accredited-investor status.